At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Radiotherapy for Breast Cancer and Metastatic Triple Negative. Completed, enrolled 17 participants across 7 sites.
Detailed Summary
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the patient and areas of cancer in their body that did not receive radiation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Metastatic Triple Negative
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Cedars-Sinai Medical Center
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartJun 2016
Primary CompletionSep 2017
Study CompletionOct 2022
TodayJul 2026
First PostedApr 6, 2016
Enrollment StartJun 3, 2016
Primary CompletionSep 26, 2017
Study CompletionOct 12, 2022
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.2 years ago
Interventions
Pembrolizumabdrug
Radiotherapyradiation